Consensus Xencor, Inc.

Stocks

XNCR

US98401F1057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:43:33 20/08/2026 +04			5-day change	1st Jan Change
27.34 ^USD	-0.64%		+19.75%	+79.82%

08-06	Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating	MT
08-06	RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating	MT

Evolution of the Average Target: Xencor, Inc.

Evolution of the Target Price: Xencor, Inc.

Changes in Analyst Recommendations: Xencor, Inc.

1e7eac70e0b488c0f8ebf.9Iy-3sHkQ-j5axOq4dzf1h0lrrACqT497ETw4KAJNaQ.he7huLCdc7qqDUTMzJbs7klBx4ZN-A5Lu3TClvdRQM6C5M62m44QrpQ4Xg~fa4a20f04465a85da66336eb7cb90ea1

Analysts' recommendations: Xencor, Inc.

08-06	Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating	MT
08-06	RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating	MT
03-24	Xencor Shares Fall After JPMorgan Downgrade	MT
03-24	JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18	MT
11-06	RBC Raises Price Target on Xencor to $19 From $18, Keeps Outperform, Speculative Risk	MT
29/10/25	Xencor Shares Rise After Barclays Upgrade	MT
29/10/25	Barclays Upgrades Xencor to Overweight From Underweight, Adjusts Price Target to $23 From $6	MT
27/10/25	RBC Raises Price Target on Xencor to $18 From $15, Keeps Outperform, Speculative Risk	MT
24/10/25	Xencor, Inc. Presents Initial Data for XmAb819, a First-In-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma	CI
14/10/25	Xencor Shares Fall After Early Commentary on Kidney Cancer Drug Trial Abstract	MT
03/09/25	Xencor Shares Fall After BofA Securities Downgrade	MT
03/09/25	BofA Securities Downgrades Xencor to Neutral From Buy	MT
21/08/25	RBC Cuts Price Target on Xencor to $15 From $32, Keeps Outperform, Speculative Risk	MT
07/08/25	Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating	MT
21/04/25	William Blair Initiates Xencor at Outperform	MT
28/02/25	RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains Outperform - Speculative Risk Rating	MT
28/02/25	Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating	MT
12/12/24	Wells Fargo Initiates Xencor at Overweight With $37 Price Target	MT
02/12/24	Piper Sandler Upgrades Xencor to Overweight, Price Target is $30	MT
26/09/24	RBC Raises Price Target on Xencor to $34 From $31, Keeps Outperform, Speculative Risk	MT
14/06/24	Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating	MT
14/06/24	BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating	MT
14/06/24	RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating	MT
13/06/24	Wedbush Cuts Price Target on Xencor to $34 From $36, Maintains Outperform Rating	MT
10/05/24	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XENCOR, INC.					+5.38%
	WUXI APPTEC CO., LTD.					+11.3%
	ARGENX SE					+6.68%
	INSMED INCORPORATED					+53.1%
	WUXI BIOLOGICS (CAYMAN) INC.					-0.85%
	BIONTECH SE					+7.26%
	GENMAB A/S					+12.01%
	PHARMAESSENTIA CORPORATION					-6.27%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+16.89%
	EXELIXIS, INC.					-2.56%
	Average					+10.29%
	Weighted average by Cap.					+11.52%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.52USD

Average target price

29.00USD

Spread / Average Target

+5.38%

High Price Target

44.00USD

Spread / Highest target

+59.88%

Low Price Target

14.00USD

Spread / Lowest Target

-49.13%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
RBC Capital Markets
JPMorgan Chase
Barclays
BofA Securities
William Blair & Co.
Wells Fargo Securities
Piper Sandler
Raymond James
BMO Capital
BTIG
Berenberg Bank
Canaccord Genuity
EF Hutton
Cowen
HC Wainwright
SMBC Nikko
Guggenheim
SVB Leerink